Merck & Co., Inc. (FRA:6MK)

Market Cap	257.57B +18.3%
Revenue (ttm)	55.37B +1.3%
Net Income	15.55B +6.6%
EPS	6.20 +8.0%
Shares Out	n/a
PE Ratio	16.57
Forward PE	23.82
Dividend	2.86 (2.77%)
Ex-Dividend Date	Dec 15, 2025

Volume	217
Average Volume	444
Open	103.80
Previous Close	103.60
Day's Range	103.20 - 103.80
52-Week Range	65.50 - 104.00
Beta	n/a
RSI	65.61
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Pharmaceutical Preparations
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6MK

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD